AnHeart Therapeutics closes USD20m Series A+

AnHeart Therapeutics recently announced that it has raised over 20 million US dollars in an oversubscribed Series A+ equity financing round.

AnHeart Therapeutics recently announced that it has raised over 20 million US dollars in an oversubscribed Series A+ equity financing round.

The round was led by China Merchants Venture Capital, with participation from existing investor, Decheng Capital, and several new institutional investors.

The funds raised in this round will be used to advance the global Phase II clinical trial of Taletrectinib and to further expand the oncology development pipeline of AnHeart Therapeutics.

Founded in November 2018, AnHeart Therapeutics is a clinical-stage biopharmaceutical company focused on the unmet clinical needs of the global market in oncology. Headquartered in Hangzhou, China, the company has branch offices in Beijing, Shanghai and New York.

AnHeart Therapeutics introduced a worldwide marketing license for Taletrectinib, a next-generation, highly potent and highly selective kinase inhibitor targeting ROS1 mutations and NTRK mutations that can cross the blood-brain barrier.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/08/16/anheart-therapeutics-closes-usd20m-series-a/.

Leave a Reply

Please Login to Comment